Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Erasmus, J. J., Gladish, G. W., Broemeling, L., Sabloff, B. S., Truong, M. T., Herbst, R. S., & Munden, R. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.144 · Cited by 476
Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study
Byrne, M. J., Davidson, J. A., Musk, A. W., Dewar, J., van Hazel, G., Buck, M., de Klerk, N. H., & Robinson, B. W. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.25 · Cited by 334
Self-citationA multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
Nowak, A. K., Byrne, M. J., Williamson, R., Ryan, G., Segal, A., Fielding, D., Mitchell, P., Musk, A. W., & Robinson, B. W. S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600505 · Cited by 225
Self-citation
Cited by
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Self-citationZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Scherpereel, A., Astoul, P., Baas, P., Berghmans, T., Clayson, H., de Vuyst, P., Dienemann, H., Galateau-Salle, F., Hennequin, C., Hillerdal, G., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00063109 · Cited by 638
van Meerbeeck, J. P., Gaafar, R., Manegold, C., Van Klaveren, R. J., Van Marck, E. A., Vincent, M., Legrand, C., Bottomley, A., Debruyne, C., & Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.20005.14.589 · Cited by 617
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Clayton, A., Mitchell, J. P., Court, J., Mason, M. D., & Tabi, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3456 · Cited by 520
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., Pisters, K., Monberg, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3943 · Cited by 467
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426
Maio, M., Scherpereel, A., Calabrò, L., Aerts, J., Perez, S. C., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 424
Self-citationRECIST revisited: A review of validation studies on tumour assessment
Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.026 · Cited by 422
Kindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420
Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 380
Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., Di Giacomo, A. M., Danielli, R., Altomonte, M., Mutti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70381-4 · Cited by 356
Measures of Response: RECIST, WHO, and New Alternatives
Jaffe, C. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5599 · Cited by 302
Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3190 · Cited by 296
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Quispel-Janssen, J., van der Noort, V., de Vries, J. F., Zimmerman, M., Lalezari, F., Thunnissen, E., Monkhorst, K., Schouten, R., Schunselaar, L., Disselhorst, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.038 · Cited by 255
Disselhorst, M. J., Quispel-Janssen, J., Lalezari, F., Monkhorst, K., de Vries, J. F., van der Noort, V., Harms, E., Burgers, S., & Baas, P. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30420-x · Cited by 250
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164
Novello, S., Pinto, C., Torri, V., Porcu, L., Di Maio, M., Tiseo, M., Ceresoli, G., Magnani, C., Silvestri, S., Veltri, A., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.05.004 · Cited by 111
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85
Mankor, J. M., Disselhorst, M. J., Poncin, M., Baas, P., Aerts, J. G. J. V., & Vroman, H. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.103040 · Cited by 45
Metadata
- Authors
- Byrne, M. J., & Nowak, A. K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 15
- Issue
- 2
- Pages
- 257-260
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2100576484
- Cited by
- 645
- References
- 5
- FWCI
- 17.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.